Gain presented additional clinical and biomarker data from Part 1 of its open-label Phase 1b study of GT-02287 in Parkinson’s disease at AD/PD 2026, and noted that some results had been previously presented in January 2026. In Part 1, 19 participants completed dosing and 16 entered an ongoing nine-month extension, with a Data Monitoring Committee review concluding the study should continue without changes. The company reported that, among participants with elevated baseline cerebrospinal fluid $(CSF)$ glucosylsphingosine (GluSph), CSF GluSph decreased after 90 days of GT-02287 treatment, and CSF DOPA decarboxylase decreased after 90 days in those with high baseline CSF GluSph. As of March 10, 2026, 14 participants in the extension had reached Day 150, and MDS-UPDRS scores were reported as stable over 150 days of dosing, with a 6.7-point difference in the combined Part II and Part III scores at Day 150 between groups defined by high versus low baseline CSF GluSph. Chief Medical Officer Jonas Hannestad said the extension is expected to complete in September 2026, with additional data planned for presentation at scientific conferences later in the year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180815PRIMZONEFULLFEED9674360) on March 18, 2026, and is solely responsible for the information contained therein.